OMA Submission on Health Canada s Proposed Regulations for Additional Cannabis Products. February 2019

Similar documents
Ontario Medical Association. Recommendations to the Ministry of the Attorney General on Recreational Cannabis Consultation

Proposed Amendments to the Cannabis Regulations: Edible Cannabis, Cannabis Extracts and Cannabis Topicals

Addition of Edibles and Other Products to Federal Cannabis Legislation

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis. February 2018

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis

Office of the Chief Medical Health Officer

The Tobacco and Vaping Products Act: Implications for E-Cigarette Point-of-Sale Promotion

FDA s Action Agenda to Reduce Tobacco Related-Cancer Incidence and Mortality

2018 OAAS CONVENTION. Fair s and Marijuana. Shawn LaPalm

Cannabis Legalization August 22, Ministry of Attorney General Ministry of Finance

Cannabis Legalization in Alberta

PA Consultation Document: Cannabis

Yukon s Proposed Framework for. Legalized Cannabis 30 GRAMS MINIMUM AGE

Cannabis Regulations Response and Update on Cannabis Legalization

Cannabis use carries significant health risks, especially for people who use it frequently and or/begin to use it at an early age.

COMMITMENT TO A TOBACCO ENDGAME IN ONTARIO

Ryan Smith, Community Planning Department Manager

Mitch Zeller, Director, Center for Tobacco Products, FDA September 19, 2013 Kansas Public Health Association

MARIJUANA: EXPLORING THE PUBLIC HEALTH APPROACH

Cannabis Retail Store Licensing in Ontario. General Committee December 10, 2018

Cannabis Legalization and Regulation in British Columbia Discussion Paper

Cannabis Legalization

Legalization of Cannabis: The Way Forward

Health Policy Committee

Cannabis Legalization and Regulation

RNAO response to proposed regulation under Smoke-Free Ontario Act, 2017

Policy Options for the Regulation of Electronic Cigarettes

Marijuana Legalization Public Health Considerations & Municipal Options

SUBJECT: Cannabis legislation and implications for the City of Burlington

A PUBLIC HEALTH APPROACH TO THE LEGALIZATION, REGULATION AND RESTRICTION OF ACCESS TO CANNABIS

Legalization and Regulation of Recreational Cannabis PRESENTATION LPPANS NOVEMBER 22, 2017

Health Canada s Proposed Approach to Managing Caffeinated Energy Drinks

January 19, Cannabis Legalization and Regulation Secretariat Address locator 0602E Health Canada Ottawa, Ontario K1A 0K9

MARKETING STANDARDS FOR MEMBERSHIP

RECREATIONAL CANNABIS LEGALIZATION IN ONTARIO

Webinar. Restricting Marketing to Children: an update from Health Canada. February 28, 2017

Electronic cigarettes: A new era for tobacco harm reduction Adapted for SW Specialist Nurses for Children in Care meeting 17 January 2017

The federal legislation, Cannabis Act that legalizes recreational cannabis comes into effect on October 17, 2018.

Brief Submitted to the Health Canada Consultation on Regulations for Cannabis Edibles, Extracts and Topicals

MARIJUANA LEGALIZATION. INITIATIVE STATUTE.

Marijuana Legalization Update

Frequently Asked Questions

UNITED STATES REGULATION OF TOBACCO PRODUCTS. Presented by Mitch Zeller Center Director FDA Center for Tobacco Products

Cannabis 101: Industry landscape and the road to edibles. Presented by: Glenn Fraser Date: May 10, 2018

Legalization of Cannabis- Overview

420 ADVISORY MANAGEMENT

Legalization of Recreational Cannabis

Copyright Canadian Nurses Association 50 Driveway Ottawa, Ont. K2P 1E2 CANADA

REDUCING YOUTH ACCESS AND APPEAL OF VAPING PRODUCTS CONSULTATION ON POTENTIAL REGULATORY MEASURES

Legalization and Regulation of Cannabis Enforcement Challenges

City of Oshawa Comments to the Provincial Government Concerning Cannabis Consumption

Policy Options for the Regulation of Electronic Cigarettes

Julia Dilley, PhD Oregon Health Authority, Public Health Division & Multnomah County Health Dept.

These documents were created to support the work of the Coalition of Colorado Campus Alcohol and Drug Educators. We welcome prevention teams at

UPDATES FROM THE FDA CENTER FOR TOBACCO PRODUCTS (CTP)

LEGALIZING & REGULATING CANNABIS IN SASKATCHEWAN

Discussion points on Bill S-5

Prince Edward Island: Preparation for Cannabis Legalization

Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse

Legalization of Cannabis: Let s Protect Future Generations POSITION PAPER

Cannabis Legalization in San Francisco

Corporate Development Committee Report

REGULATING CANNABIS IN NUNAVUT A Proposal for Consideration and Discussion

The Economics of Smoking

Torkin Manes LegalPoint

OCSA HEALTH CANADA NOTICE OF INTENT - Vape Products

Cannabis, the law, and housing

Cannabis: What Parents/Guardians and Caregivers Need to Know

Legalization of Recreational Cannabis. Mary Ellen Bench City Solicitor, City of Mississauga November 26, 2018

CANNABIS AND CANADA S CHILDREN AND YOUTH CPS Podcast

CORPORATE POLICY MANUAL. 1. SCOPE 1.1 Authority This policy is issued under the authority of the Senior Executive Team.

Update on the Legalization and Regulation of Cannabis. January 8, 2018 Regular Meeting of Delta Council

Submission to the Oireachtas Joint Committee on Health and Children

Cannabis Legalization Proposed Bylaws

Ontario s Doctors Help You Make Informed Decisions: Clearing the Air About Adult Use Cannabis

CMA Response: Health Canada s Medical Marihuana Regulatory Proposal. Submitted to the Office of Controlled Substances Health Canada.

Legalization of non-medical Cannabis OPSBA Update September 08, 2017

Tobacco Control. (Update 2008)

Life s brighter under the sun MEDICAL CANNABIS AND GROUP BENEFITS PLAN COVERAGE

burden of tobacco Key Findings about the Use and Consequences of Tobacco in Peel

AMA Submission House of Representatives Standing Committee on Health and Ageing inquiry into the

Mr José Manuel Barroso President of the European Commission Rue de la Loi 200 B-1049 Brussels. Courtesy translation

A Public Health Framework for Legalized Retail Marijuana: Avoiding a New Tobacco Industry

Model. Medical Access to Marihuana first established on a case by case basis using exemptions

COUNCIL INFORMATION PACKAGE. March 29, Table of Contents

The Shifting Federal Regulation of Cannabis Products

CANNABIS IN CANADA. Prepared by: Shaun Casey, CEO Richard Hong, VP Sales OUR VIEWS ON BILL C-45 - TO THE STANDING COMMITTEE ON HEALTH

Alberta s System for Legalized Cannabis. alberta.ca/cannabis

Advancing the Tobacco Endgame: Evidence and Progress. alpha Board Meeting April 24 th, 2015 Robert Schwartz

Cannabis and the Workplace AMCTO Zone 1 October 11, 2017

Dear Minister Farnworth

Frequently Asked Questions

ACHIEVING SMOKEFREE AOTEAROA BY2025

APPROVED = a Majority of subcommittee members present voted yes on the recommendation

WHO Framework Convention on Tobacco Control

Marijuana 101. Cristal Connelly- Marijuana Prevention & Education Consultant Washington State Department of Health- Community Based Prevention

AGENDA. 9:00 Sign-in and introductions 9:15 Marijuana 10:30 Break 10:45 Opioid Prevention 11:30 Discussion & Wrap-Up

PROPOSED APPROACH TO THE REGULATION OF CANNABIS SUMMARY OF COMMENTS RECEIVED DURING THE PUBLIC CONSULTATION

SUBSTANCE USE GUIDELINES

PLANNING IMPLICATIONS FOR CANNABIS LEGISLATION. Zone 7 & 8 Spring Workshop April 19, 2018

Transcription:

OMA Submission on Health Canada s Proposed Regulations for Additional Cannabis Products February 2019

OMA Submission on Health Canada s Proposed Regulations for Additional Cannabis Products The Ontario Medical Association (OMA) appreciates the opportunity to comment on the proposed regulations for additional cannabis products, namely edible cannabis (including beverages), cannabis extracts and cannabis topicals. This submission intends to propose recommendations to the key issues and questions identified by the federal government. The OMA s recommendations on the proposed regulations are based on public health and harm reduction approaches. Recommendations and key learnings from other stakeholders, including other jurisdictions and the Canadian Medical Association were considered when this submission was written. As an overarching principle, the OMA would like to reiterate that despite its popularity, recreational cannabis is associated with several negative health risks, especially for those who use it frequently or begin to use it at an early age. These health impacts include addictive consequences, a range of respiratory and circulatory diseases and disorders, cognitive effects as well as harmful effects on the mental health of some individuals. The health risks caused by recreational cannabis use can best be avoided by abstaining from cannabis use. The OMA supports much of the proposed regulations and the intent of the regulations to establish protection around the legalization of additional cannabis products. The federal government, for the most part, has introduced appropriate safeguards given the evidence that is currently available regarding recreational cannabis. That said, the OMA feels it is important to note that there is a need for more research on recreational cannabis and at this time there is a gap in knowledge. As such, greater research is needed. The content of this submission will focus on specific sections of the proposed regulations (and will be divided as such), namely: THC limits, Product Ingredients and Flavouring, Packaging and Labelling, and Additional Considerations. Page 1 of 7 November 2018

THC Limits Legalizing additional recreational cannabis products gives the federal government an opportunity to regulate the substance as well as mitigate some of the associated health risks. A key element to regulating recreational cannabis is to set a limit on the amount of THC allowed in each product. Canada has a unique opportunity in regulating recreational sales as it can implement progressive regulations based on lessons learned from other jurisdictions that have legalized cannabis. The proposed regulations from the federal government do outline strict THC limits for each new class of cannabis products. While, the OMA supports the proposed implementation of restrictions on THC limits, stricter limits would be more in line with a harm reduction approach. If we look to other jurisdictions for lessons learned, we would predict that cannabis-infused edibles will have a strong hold in the cannabis market share. Since legalizing cannabis in both Colorado and Washington states, they have seen continued growth in sales of cannabis edibles (1). In fact, sales of cannabis-infused edibles had increased by 134% in the first quarter of 2015 compared to the same period in 2014 (1). Cannabis-infused edibles have a broad appeal for several reasons. First, novice cannabis users often find cannabis-infused edibles such as brownies and cookies attractive (1). Secondly, restrictions on where cannabis can be smoked in both public and private spaces may increase interest in the edible market (1). This is noteworthy as it is not yet clear if the same restrictions on where cannabis can be smoked will apply to edible cannabis. Lack of regulation around edible products in Colorado s initial phase of legalization led to several unintended public health consequences, including accidental overconsumption and overdoses, increased emergency room visits and calls to poison control lines (1). A key lesson learned from other jurisdictions to best avoid the unintended consequences is to implement strict THC limits and portion sizes for cannabis-infused products (1). Should the proposed regulations be passed, no more than 10 mg of THC will be permissible per package of edible cannabis product and 1000 mg of THC per package of cannabis extracts. No guidance on serving size is outlined in the proposed regulations other than a limit of 10 mg per unit of cannabis extracts intended for ingestion. While the proposed THC limits per serving size are within the limits of other jurisdictions, they are higher than what many cannabis advocates would suggest for first time users when applying a harm reduction approach. This is critical given that no guidance for serving or dosage sizes is outlined in the proposed regulations. Should the THC limit be set at 10mg for edible cannabis products and 1000 mg per package of cannabis extracts, guidance should be outlined for dosage and serving size. The recommended serving size for both edible cannabis products and cannabis extracts should be 5 mg of THC, which is in line with a harm reduction approach. Recommendation 1: The recommended serving size for edible products (solid or beverage) should be 5 mg of THC/serving. Page 2 of 7

Product Ingredients and Flavouring Parameters around product ingredients and product flavours are also key elements that must be regulated to mitigate some of the negative health impacts of recreational cannabis use. The federal government has introduced appropriate safeguards to restrict caffeine, nicotine, alcohol, added vitamins and minerals, sugar, colours and sweeteners to the new classes of cannabis products. The OMA supports the federal government s decision to implement restrictions on certain flavours, such as dessert or confectionary flavours, that are often appealing to youth. The flavouring restrictions are outlined to be consistent with rules that apply to vaping products under the Tobacco and Vaping Products Act. That said, there is evidence that banning all flavoured tobacco, including menthol, has shown to be an effective public health measure to reduce uptake in regular use. The federal government should apply lessons learned from banning flavoured tobacco to underpin the flavouring ban for cannabis products. Recommendation 2: All flavouring should be restricted for cannabis extract (ingested or inhaled) products. Labelling and Packaging In addition to regulations on THC limits, product ingredients and flavours, labelling and packaging are key components to ensuring the negative health impacts of recreational cannabis use are mitigated. The federal government has introduced proposed regulations for the new classes of cannabis to have specific label requirements on top of the already required primary plain packaging and labelling requirements. The OMA is in support of the additional requirements set out in the proposed regulations. If passed, these regulations will necessitate edible cannabis products to have similar labelling requirements to food, including a cannabis-specific Nutrition Facts Table, will prohibit the new classes of cannabis to associate with alcoholic beverages and from making health and cosmetic benefit claims and/or claims of being part of a specific diet. That said, there is no guidance in the proposed regulations to ensure serving size and/or dosage is included in the label. As noted in the THC Limits section of this submission, suggested serving and dosage sizes are recommended and should be clearly marked on product labels. Further, the way in which cannabis is consumed will impact when the user feels the effect. This is especially important when considering individuals consuming cannabis-infused edible products where it can take several hours for THC to take full effect. In some cases, this has led to users consuming more cannabis when the desired effect has not been felt and resulted in stacked dosing of cannabis and consequently accidental overconsumption or overdoses. Warning labels on products where a delayed effect is likely should outline that a postponed result is expected to best avoid users from overconsuming THC or overdoses. Moreover, with additional classes of cannabis legalized, there is room for consumer confusion on the quantity of the product in Page 3 of 7 November 2018

question. This could also lead to overconsumption and overdoses for individuals using new classes of cannabis products. To avoid or limit such incidents, labels should include an equivalency factor, that outlines the quantity of the given cannabis product that is equivalent to one gram of dried cannabis. Finally, the proposed regulations include allowances for small product packages to have the ability to use peel-back or fold-out labels to display certain required information. The OMA believes that public health warnings on recreational cannabis products should be a core component to public education. Front of the label packaging should be standard regardless of the product package size. Recreational cannabis products labelling regulations should be in line with federal tobacco products labelling regulations that state that 75% of the front and back of cigarette and little cigar packages be covered in health warning messages. Recommendation 3: Serving size (for edible products) and recommended dosage (for cannabis extract and topical products) should be included on the product label. Recommendation 4: Edible product warning labels should outline that there may be a delayed effect or that the user may not feel the full effect of consuming cannabis immediately. Recommendation 5: A gram equivalency factor is considered as an additional requirement for labels. Recommendation 6: Recreational cannabis product labelling regulations should be in line with federal tobacco products labelling regulations that state that 75% of the front and back of cigarette and little cigar packages be covered in health warning messages. Additional Considerations Minimum age for possessing, using and purchasing recreational cannabis The federal government has outlined that one of the key reasons for legalizing cannabis is to protect youth and to establish safeguards so that illegal cannabis is not accessible to underage individuals. In order to achieve this goal, a minimum age to purchase, possess, and use recreational cannabis has been set at 18 with the ability for provinces and territories to adjust the minimum age upward. Establishing a minimum age has been an important control measure for both alcohol and tobacco in Canada. Regarding a minimum age for recreational cannabis, the government must focus first and foremost on health risks. There is strong evidence showing recreational cannabis use impacts brain development. It is known that the brain continues to develop through early adulthood, until the age of 25 (3,4). Adopting a minimum age of under 25 for recreational cannabis use ignores scientific evidence around the negative health impacts on brain development. Therefore, the OMA advocates that the federal government reconsider the minimum age for purchase, possession and use of cannabis and adjust it to 25. Page 4 of 7

Recommendation 7: The minimum age for purchasing, possessing and using recreational cannabis should be reconsidered and set at 25, given the negative impact that recreational cannabis can have on health, particularly on brain development. Regulating recreational cannabis sales There must be strict regulations implemented on the marketing of recreational cannabis, using the current regulations for marketing tobacco as the minimum. Regulatory frameworks that address marketing for tobacco, vaping products and recreational cannabis should be updated in lockstep. Recommendation 8: There must be strict regulations implemented on the marketing of recreational cannabis, using current regulations for marketing tobacco as the minimum. Planning public education and research It is critical that the federal government integrate the additional cannabis products into existing public education campaigns and or develop new campaigns for edible cannabis and cannabis extracts and topicals. Regardless of whether the government expands its current campaign or develops a new one, any public education campaign should use a public health approach that focuses on prevention and increasing awareness of the risk factors associated with recreational cannabis use. General education and awareness campaigns should be geared toward the general public. More focused public education should be developed to target youth as well as specific populations that are more at risk for cannabis use and its adverse effects (5). Current public education materials should be updated, and revised campaigns and materials should be deployed before the new classes of cannabis become legal. Successful campaigns used in the past have increased awareness of the health impacts of tobacco and alcohol and have led to greater public knowledge around the issues as well as a decrease in the number of users. Principles from these campaigns could serve as a foundation to underpin current and future work around public awareness of the harmful risks of recreational cannabis use, no matter the consumption method. Physicians play a critical role in planning and executing education on harmful health impacts that cannabis can have. Patients turn to physicians as a trusted voice on a wide array of health issues, including the impacts of cannabis in all forms of consumption. However, to date, there have been insufficient resources allocated to properly research cannabis use at a national level. This lack of evidence-based information poses a public health risk and leaves physicians ill-equipped to inform and best support patients. Recommendation 9: Public education campaigns should be developed or updated to integrate additional cannabis products. Public education campaigns should focus on prevention and increasing awareness of the risk factors associated with recreational cannabis use and should be deployed before additional cannabis products become legal. Recommendation 10: The federal government should invest in necessary research to inform physicians and health care providers about the health impacts of recreational cannabis use. Page 5 of 7 November 2018

Summary of Recommendations 1. The recommended serving size for edible products (solid or beverage) should be 5 mg of THC/serving. 2. All flavouring should be restricted for cannabis extract (ingested or inhaled) products. 3. Serving size (for edible products) and recommended dosage (for cannabis extract and topical products) should be included on the product label. 4. Edible product warning labels should outline that there may be a delayed effect or that the user may not feel the full effect of consuming cannabis immediately. 5. A gram equivalency factor is considered as an additional requirement for labels. 6. Recreational cannabis product labelling regulations should be in line with federal tobacco products labelling regulations that state that 75% of the front and back of cigarette and little cigar packages be covered in health warning messages. 7. The minimum age for purchasing, possessing and using recreational cannabis should be reconsidered and set at 25, given the negative impact that recreational cannabis can have on health, particularly on brain development. 8. There must be strict regulations implemented on the marketing of recreational cannabis, using current regulations for marketing tobacco as the minimum. 9. Public education campaigns should be developed or updated to integrate additional cannabis products. Public education campaigns should focus on prevention and increasing awareness of the risk factors associated with recreational cannabis use and should be deployed before additional cannabis products become legal. 10. The federal government should invest in necessary research to inform physicians and health care providers about the health impacts of recreational cannabis use. Page 6 of 7

References 1. A framework for the legalization and regulation of cannabis in Canada: the final report of the Task Force on Cannabis Legalization and Regulation Government of Canada; Dec, 2016. Available from: https://www.canada.ca/en/health-canada/services/drugsmedication/cannabis/laws-regulations/task-force-cannabis-legalizationregulation/framework-legalization-regulation-cannabis-in-canada.html#a2.4 2. Banning flavoured tobacco products - Canadian Cancer Society [Internet]. www.cancer.ca. [cited 2019Jan28]. Available from: http://www.cancer.ca/en/get-involved/take-action/whatwe-are-doing/tobacco-control/banning-flavoured-tobacco-products-sk/?region=sk 3. Lebel C, Beaulieu C. Longitudinal Development of Human Brain Wiring Continues from Childhood into Adulthood [Internet]. Journal of Neuroscience. Society for Neuroscience; 2011 [cited 2019Feb4]. Available from: http://www.jneurosci.org/content/31/30/10937 4. Caballero A, KY Seng. Association of cannabis use during adolescence, prefrontal CB1 receptor signaling, and schizophrenia. 2012. Frontiers in Pharmacology. 3:101 5. Cannabis Policy Framework. (2014). [ebook] Toronto: Centre for Addiction and Mental Health. [cited 2019Feb4]. Available from: https://camh.ca/en/hospital/about_camh/influencing_public_policy/documents/camhcann abispolicyframeowrk.pdf Page 7 of 7 November 2018